These results demonstrate that oncogene-induced ROS synthesis can be exploited by pharmacologically targeting Nox4 with specific inhibitors to achieve selective and potent cancer cell growth inhibition in synergy with standard care of therapeutic treatments. This evidence concerns the gene NOX4 and cancer.